Status:
TERMINATED
Half-Dose Radiopharmaceutical in Wide Beam Reconstruction
Lead Sponsor:
Edwin Wu
Collaborating Sponsors:
Astellas Pharma Global Development, Inc.
Conditions:
Myocardial Infarction
Ischemic Heart Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study is recruiting patients already scheduled for a single photon emission computed tomography myocardial perfusion imaging (SPECT-MPI) test. SPECT-MPI is a nuclear imaging technique that uses a...
Detailed Description
Subjects in this study will proceed to the nuclear cardiology laboratory for their scheduled nuclear stress test. After informed consent is obtained, the study doctor or research staff member will ask...
Eligibility Criteria
Inclusion
- Patients over the age of 18 years
- Undergoing nuclear stress testing
- History of myocardial infarction, cardiomyopathy, heart failure or prior nuclear studies with resting perfusion defects
Exclusion
- Unwilling or unable to undergo an additional resting SPECT acquisition
- Clinical contraindications to nuclear stress testing including acute myocardial infarction
- For patients undergoing exercise treadmill stress testing:
- Left bundle branch block or artificial ventricular pacemaker
- For patients undergoing regadenoson (Lexiscan) stress testing:
- Moderate to severe chronic obstructive pulmonary disease or asthma, second- or third degree atrioventricular block or sinus node disease (unless patients have a functioning artificial pacemaker), known hypersensitivity to aminophylline or adenosine
- Inability to give informed consent
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT01499654
Start Date
October 1 2011
End Date
December 1 2014
Last Update
February 24 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern University
Chicago, Illinois, United States, 60611